On December 10, DARWIN Precision announced that it had signed a memorandum of understanding (MOU) with LAUNXP Biomedical, a company focused on the development of new targeted anti-cancer drugs. The two parties will jointly develop innovative new dosage forms of anti-cancer drugs and use the advanced microneedle technology of MicroDoctor Biomedical Inc. (established by DARWIN Precision Co., Ltd.) to change the way traditional drugs are delivered, bringing more efficient and convenient treatment options to cancer patients.
MicroDoctor Biomedical Inc. has applied Darwin precisions’s core technology to the medical field and developed microneedle patch technology. Through continuous breakthroughs, we have successfully solved the previous problems of uneven microneedle structure and different needle lengths, innovatively improved the shape accuracy of microneedles, and significantly improved the effect of the patch. This technology can not only be widely used in the fields of medicine, medical beauty and vaccines, but also opens up new possibilities for drug delivery.
The drug delivery method of microneedle technology is different from the traditional transdermal absorption method. The microneedle patch developed by MicroDoctor Biomedical team is able to precisely release drugs into the inner layers of the skin while penetrating the stratum corneum. The application of this innovative technology is painless and non-invasive, and can achieve more efficient and precise drug release, improving patients’ treatment experience. This collaboration with LAUNXP will combine MicroDoctor’s microneedle technology with LAUNXP’s drug products to provide patients with more convenient treatment options.
LAUNXP Biomedical has extensive experience in the research and development of anti-cancer drugs, and has collaborated with many top research institutions to develop a variety of innovative drugs for cancer. Through this collaboration, LAUNXP will combine MicroDoctor Biomedical’s microneedle technology with its new multi-target anti-cancer drug LXPA1788, and plans to test it in animal experiments and clinical trials to evaluate the drug’s absorption rate and efficacy in the microneedle system. This cooperation not only makes the use of drugs more convenient, but also is expected to significantly improve the treatment effect and create a new situation in cancer treatment.
With the maturity and application of microneedle technology, MicroDoctor Biomedical team will further deepen its layout in the medical field and bring more innovative products in the future to help cancer patients around the world embrace new hope.
